Tau Inhibitor Drugs Pipeline Market Research Report 2022: Development Stage, Product Type, Molecule Type and Route of Administration

DUBLIN, March 04, 2022–(BUSINESS WIRE)–The “Tau Inhibitor – Pipeline Insight, 2022” clinical trials have been added to from ResearchAndMarkets.com offer.

The “Tau Inhibitor – Pipeline Insight, 2022” report offers a comprehensive overview of the therapeutic pipeline (under development) scenario and growth prospects across Tau Inhibitor development.

The report provides detailed pipeline landscape coverage for this mechanism of action, equipped with data from multiple sources with comprehensive pipeline analysis by development stage, associated indications, route of administration, and molecule type.

Descriptive coverage of pipeline development activities for the Tau Inhibitor

Therapeutic pipeline development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and preclinical studies, designations, collaborations , license agreements, grants, technologies and patent details.

Pipeline Therapeutics Evaluation of Products for Tau Inhibitor

The report evaluates products in the active tau inhibitor pipeline by development stage, product type, molecule type, and route of administration.

Report scope

  • Provides an overview of therapeutic pipeline activity for the Tau Inhibitor

  • Showcases the tau inhibitor pipeline throughout the product development cycle, including all clinical and non-clinical stages

  • Offers detailed Tau Inhibitor therapeutic product profiles with key development activity coverage, including licensing and collaboration agreements, patent details, designations, technologies, indications and chemical information

  • Therapeutic assessment of active pipeline products by stage, product type, molecule type, and route of administration

  • Coverage of Inactive and Discontinued Tau Inhibitor Pipeline Projects

Main topics covered:

1. Presentation of the report

2. Tau Inhibitor – Overview

3. Pipeline Therapeutics

4. Benchmarking

5. Clinical Stage Tau Inhibitor Pipeline Products

6. Non-Clinical Stage Tau Inhibitor Pipeline Products

7. Therapeutic Assessment: Active Products

  • Pipeline assessment by route of administration

  • Pipeline assessment by stage and route of administration

  • Pipeline assessment by molecule type

  • Pipeline assessment by stage and molecule type

8. Inactive Pipeline Products

appendix

Companies cited

  • Axon Neuroscience

  • TauRx Therapeutic Ltd.

  • Cortex Biosciences

  • Teijin Pharma

  • Merck

  • Eli Lily

  • Bristol Myers Squibb

  • Abbie

  • Mayssen

  • AC Immune

For more information on this clinical trial report, visit https://www.researchandmarkets.com/r/leoc6p

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220304005304/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Comments are closed.